Cyclerion Therapeutics Inc [NASDAQ: CYCN] closed the trading session at $3.25 on 2025-09-24. The day’s price range saw the stock hit a low of $3.0201, while the highest price level was $3.76.
The stocks have a year to date performance of 10.92 percent and weekly performance of 39.48 percent. The stock has been moved at 19.49 percent over the last six months. The stock has performed 27.70 percent around the most recent 30 days and changed 9.40 percent over the most recent 3-months.
If compared to the average trading volume of 122.13K shares, CYCN reached to a volume of 14364032 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cyclerion Therapeutics Inc [CYCN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CYCN shares is $80.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CYCN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Cyclerion Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 20, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on September 24, 2021, representing the official price target for Cyclerion Therapeutics Inc stock.
The Price to Book ratio for the last quarter was 1.17, with the Price to Cash per share for the same quarter was set at 0.90.
CYCN stock trade performance evaluation
Cyclerion Therapeutics Inc [CYCN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 39.48. With this latest performance, CYCN shares gained by 27.70% in over the last four-week period, additionally plugging by 19.49% over the last 6 months – not to mention a rise of 0.93% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYCN stock in for the last two-week period is set at 66.98, with the RSI for the last a single of trading hit 0.34, and the three-weeks RSI is set at 0.29 for Cyclerion Therapeutics Inc [CYCN]. The present Moving Average for the last 50 days of trading for this stock 2.62, while it was recorded at 2.81 for the last single week of trading, and 2.96 for the last 200 days.
Cyclerion Therapeutics Inc [CYCN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cyclerion Therapeutics Inc [CYCN] shares currently have an operating margin of -172.72% and a Gross Margin at 0.00%. Cyclerion Therapeutics Inc’s Net Margin is presently recorded at -89.51%.
Cyclerion Therapeutics Inc (CYCN) Capital Structure & Debt Analysis
According to recent financial data for Cyclerion Therapeutics Inc. ( CYCN), the Return on Equity (ROE) stands at -22.43%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -20.03%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Cyclerion Therapeutics Inc’s Return on Invested Capital (ROIC) is -22.71%, showcasing its effectiveness in deploying capital for earnings.
Cyclerion Therapeutics Inc (CYCN) Efficiency & Liquidity Metrics
Based on Cyclerion Therapeutics Inc’s (CYCN) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Cyclerion Therapeutics Inc (CYCN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Cyclerion Therapeutics Inc. (CYCN) effectively leverages its workforce, generating an average of -$1950000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.03% and a Quick Ratio of 5.03%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Cyclerion Therapeutics Inc [CYCN] stock
With the latest financial reports released by the company, Cyclerion Therapeutics Inc posted -3.82/share EPS, while the average EPS was predicted by analysts to be reported at -6.4/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.58. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CYCN.
Cyclerion Therapeutics Inc [CYCN]: Institutional Ownership
There are presently around $11.44%, or 16.69%% of CYCN stock, in the hands of institutional investors. The top three institutional holders of CYCN stocks are: SLATE PATH CAPITAL LP with ownership of 0.36 million shares, which is approximately 14.2582%. MFN PARTNERS MANAGEMENT, LP, holding 0.17 million shares of the stock with an approximate value of $$0.39 million in CYCN stocks shares; and MFN PARTNERS MANAGEMENT, LP, currently with $$378.99 million in CYCN stock with ownership which is approximately 6.5648%.
